Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer

Early Stage Breast Cancer Clinical Trial

Official title:

Feasibility and Safety of Avoiding Granulocyte Colony-stimulating Factor Prophylaxis During the Paclitaxel Portion of Dose Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02698891
• Other study ID #: 15-516
• Status: Completed
• Phase: Phase 2
• Start date: April 7, 2016
• Est. completion date: November 2021

Study information

• Verified date: April 2022
• Source: Dana-Farber Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This research study is testing the safety and feasibility of delivering the 4 cycles of 'dose-dense' paclitaxel without the use of Neulasta (Pegfilgrastim) as a Granulocyte Colony-stimulating Factor (G-CSF) support. The research study is for participants who have early stage breast cancer and have been recommended to receive a standard chemotherapy regimen, doxorubicin/cyclophosphamide (AC) plus Paclitaxel (T), in what is called a "dose-dense" fashion to prevent recurrences.

Description:

Low white cell blood counts increase the risk of infections; thus, in order to give each cycle of chemotherapy, white blood cell count must have recovered adequately in between cycles. Traditionally, this regimen has been given with the use of a medicine called Neulasta (Pegfilgrastim) to speed the recovery of the white blood cell count in order to maximize the chances that the next cycle of chemotherapy can be given on time.

The names of the study interventions involved in this study are:

-- Neulasta (Pegfilgrastim)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 127
• Est. completion date: November 2021
• Est. primary completion date: December 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Patients must have histologically or cytologically confirmed Stage I-III breast cancer (as defined by the revised, American Joint Committee on Cancer 7th edition criteria) and be at sufficient risk for tumor recurrence. Staging studies to exclude metastatic disease are not required in asymptomatic patients. However, patients with findings considered suspicious for metastatic disease on any staging studies that are obtained need to be evaluated to exclude stage IV breast cancer.

• Patients must be deemed by their treating oncologist as candidates for (neo) adjuvant chemotherapy with dose dense AC and T.

• Age = 18 years and < 65 at the time of informed consent.

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) = 1.

• Any grade 3 or clinically significant grade 2 treatment-related non-hematological toxicity must be resolved to grade 1 before retreatment with chemotherapy (with exception of alopecia)

• Laboratory Evaluations:

• Adequate blood marrow function defined as:

• Absolute neutrophil count (ANC) =1500 µL

• Hemoglobin =9.0 g/dl

• Platelets =100,000/mm3

• Adequate hepatic function defined as:

• Total bilirubin = 1.2 institutional upper limit of normal (ULN)

• Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase = 1.5 X upper limit normal (ULN)

• Adequate renal function defined as:

--- Serum creatinine = 1.5 X ULN

• Premenopausal women (including women who have had a tubal ligation and for women less than 12 months after the onset of menopause) must have a negative serum pregnancy test.

• Patients with risk factors for Hepatitis B or C should be tested (anti-hepatitis C virus (HCV) antibody, hepatitis B surface antigen [HBsAg] or Hepatitis B core antibody). Risk factors include: history of unprotected sexual intercourse, intravenous drug use, or originally from endemic regions. If infection is suspected, hepatitis B virus (HBV) DNA and HCV RNA should be requested as appropriate.

• Note: Patients with positive Hepatitis B or C serologies without known active disease must meet the eligibility requirements for ALT, AST, total bilirubin, and alkaline phosphatase and must have a normal international normalized ratio (INR) on at least two consecutive occasions, separated by at least 1 week, within the 30 day screening period.

• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

• Patients who have received previous cytotoxic chemotherapy including an AC-T regimen or previous therapeutic radiation therapy for any reason in the last 5 years. Because of possible limitations in bone marrow reserve, patients with such prior treatments are not appropriate candidates for this trial. Patients who have had prior hormonal therapy (for instance, tamoxifen for prevention of breast cancer) are eligible. Patients who have participated in a window study (treatment with an investigational agent prior to surgery for =2 weeks) are eligible but must have discontinued the investigational agent at least 14 days before enrollment.

• Participants who are receiving any other investigational agents

• Have had at least one prior episode of fever and neutropenia (ANC< 500/mm3 or expected to fall below < 500/mm3) during AC.

• Patients taking lithium.

• Patients receiving chronic treatment with oral steroids or another immunosuppressive agent (excluding steroids as part of the chemotherapy pre-medication or emetic medication).

• Known HIV-positive individuals or with any immunodeficiency status.

• Patients with history of hematologic disease, including myelodysplasia or bone marrow malignancies.

• History of allergic reaction attributed to compounds of similar chemical or biologic composition to Paclitaxel, which cannot be managed by premedication.

• Currently pregnant or breast-feeding.

• Uncontrolled intercurrent illness including, not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or other significant diseases or disorders that, in the investigator's opinion, would exclude the subject from participating in the study.

Related Conditions & MeSH terms

• Breast Neoplasms
• Early Stage Breast Cancer

Intervention

Drug:
• Paclitaxel

• Neulasta

Locations

Country	Name	City	State
United States	Dana-Farber Cancer Institute	Boston	Massachusetts
United States	Dana-Farber/New Hampshire Oncology-Hematology	Londonderry	New Hampshire
United States	Dana-Farber at Milford Regional Cancer Center	Milford	Massachusetts
United States	Dana-Farber Cancer Institute at South Shore	Weymouth	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Dana-Farber Cancer Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of Paclitaxel Treatment Completion Within 7 Weeks	Rate of participants who completed Paclitaxel treatment in 7 weeks while omitting Neulasta™ (Pegfilgrastim). Neulasta is administered based on the following pre-specified safety criteria.; The patient experiences a prior episode of fever and neutropenia.; If the patient has an active infection this decision will be at provider discretion.	7 Weeks
Secondary	Rate of Grade 3-5 Neutropenia	Percentage of participants experiencing grade 3-5 neutropenia per Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. while on treatment.	While on study, up to 6.2 months
Secondary	Rate of Grade 3-4 Toxicities, Excluding Neutropenia	Percentage of participants experiencing a grade 3 or 4 toxicity excluding grade 3 or 4 neutropenia or febrile neutropenia per Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.	While on study, up to 6.2 months
Secondary	Rate of Chemotherapy Dose Reductions	Percentage of participants experiencing dose reductions due to adverse events.	While on treatment, up to 2.3 months
Secondary	Percentage of Participants Who Received All Planned Chemotherapy Cycles	Percentage of Participants who received all planned chemotherapy cycles.	While on treatment, up to 2.3 months
Secondary	Rate of Hypersensitivity Reactions on Cycles 3-4 of Paclitaxel, When Steroid is Avoided	The percentage of participants who experienced a hypersensitivity reaction on cycles 3 and 4 without use of dexamethasone (a steroid)..	While on treatment, up to 2.3 months
Secondary	Number of Participants With Dose Delays by Reason for Delay	Number of participants with dose delays due to various different adverse events. Adverse events classified using CTCAEv 4.0.	While on treatment, up to 2.3 months
Secondary	Median of Savings When Omitting Pegfilgrastim From Treatment.	An algorithm was used to estimated median and range of potential savings per 100 patients if the use of pegfilgrastim was omitted from treatment. The algorithm is designed assuming an average wholesale price in the United States ranging from $1,361 to $4,655 for myeloid growth factors such as filgrastim (8 days of growth factor support/cycle) and peg-filgrastim ($5,443 to $18,622 for 4 cycles on the basis of April 2019 Medicare Part B Drug Average Sales Price), and applying a 95.7% reduction in the use of pegfilgrastim during paclitaxel.	While on treatment, up to 2.3 months